What happened with MGNX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
MacroGenics develops cancer drugs using its antibody-engineering platforms, advancing some candidates itself and others with pharmaceutical partners. Collaboration payments provide most of its revenue: partners pay for research, licensing rights and progress toward development, regulatory and sales milestones. Gilead funds work on MGD024 and other research programs, while Incyte leads development and commercialization of ZYNYZ. MacroGenics also receives milestone payments through retained economic rights in Sanofi’s TZIELD.
Contract development and manufacturing provides another substantial revenue stream. Its Rockville, Maryland facility makes antibody drug substance for pharmaceutical customers, with Incyte supplying most of this manufacturing revenue. This work offsets much of the facility’s operating costs, but depends on securing customer production work and maintaining regulatory compliance. MacroGenics no longer sells drugs directly after selling MARGENZA’s global rights to TerSera; it continues to manufacture drug substance for MARGENZA and ZYNYZ.
Collaboration income varies with partner decisions and milestone timing. Future payments depend on successful trials, regulatory approvals and commercial sales, and the company has little internal sales or distribution capability. Its own development work also faces a current regulatory restriction: an FDA partial clinical hold on the LINNET study of lorigerlimab prevents new patient enrollment until the hold is lifted.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
MacroGenics also depends on manufacturing demand from privately held TerSera, which acquired MARGENZA and buys its drug substance from MacroGenics.
Incyte pays MacroGenics for rights to develop and sell the cancer medicine ZYNYZ and for substantial clinical and commercial manufacturing services. Watch ZYNYZ development milestones and manufacturing demand rather than ongoing sales royalties, which MacroGenics sold in June 2025.
Gilead funds MacroGenics' antibody development by paying for the right to choose programs and obtain exclusive licenses, with further payments and royalties contingent on their progress. Its selection and licensing of a second research program brought MacroGenics $25 million in December 2025; watch further licensing decisions and MGD024 development.
Sanofi owns the acquired Provention business behind TZIELD, whose regulatory progress and sales can trigger payments retained by MacroGenics. Two regulatory milestones generated $50 million for MacroGenics in 2025; reaching a specified TZIELD sales level could trigger another $50 million.
Xencor competes with MacroGenics in engineered antibodies that bind multiple targets and bring T cells into action against cancer. Xencor earns upfront fees, milestone payments and royalties from partners licensing its candidates, making its cancer-antibody development and licensing progress worth watching alongside MacroGenics' programs.
Zymeworks competes with MacroGenics in cancer antibodies that carry a drug payload—ADCs—and antibodies that bind multiple targets. Both license selected assets to partners for milestone payments and royalties, so Zymeworks' cancer-pipeline progress and partner payments offer a comparison for MacroGenics' development and licensing business.
Genmab competes with MacroGenics in drug-carrying antibodies, or ADCs, and treatments that engage T cells against cancer through multiple targets. Its marketed cancer medicine Tivdak and partner-funded milestone and royalty revenue offer a more commercially established comparison for MacroGenics' antibody programs.
Emergent BioSolutions pays MacroGenics to develop and manufacture bulk drug substance, generating $10.7 million of MacroGenics revenue in 2025. Watch demand for these manufacturing services: the contracts pay fixed fees plus reimbursement of materials and other development and manufacturing costs.
IDEAYA competes with MacroGenics' B7H3-directed cancer antibodies through IDE034, an antibody carrying a drug payload that targets both B7H3 and PTK7. Watch IDE034's development as a competing two-target approach; MacroGenics' B7H3 ADCs are earlier-stage programs.
Janux Therapeutics' clinical progress is a competitive benchmark for MacroGenics because both develop treatments that engage T cells against cancer through multiple targets. Watch its Phase 1 JANX007 trial in adults with metastatic castration-resistant prostate cancer and JANX008 trial in multiple solid tumors; Janux has no product-sales revenue yet.
CytomX identifies MacroGenics as a competitor in treatments that engage T cells against cancer, while developing biologic drugs designed to activate in tumors. Its PROBODY technology masks a drug's binding site until the mask is released in the tumor environment, making progress on tumor activity and reduced healthy-tissue toxicity relevant to the competitive comparison.
AstraZeneca competes with MacroGenics' DART program through antibodies targeting PD-1 or PD-L1 together with CTLA-4, and also develops competing drug-carrying antibodies, or ADCs. Watch those bispecific antibodies' clinical progress: MacroGenics identifies them as direct competitors backed by significantly greater resources.
Gilead Sciences Inc earningsGILD
Gilead’s report and related disclosures can show whether it is advancing programs with MacroGenics, a sign of whether further collaboration payments may become possible.
Look for any disclosed program selection, licensing decision, or progress on MGD024. If a program advances and meets the agreement’s conditions, MacroGenics may receive further payments; if progress stalls or a program is set aside, those payments remain uncertain—not earned revenue.
Incyte Genomics Inc earningsINCY
Incyte’s report and disclosures can show demand for MacroGenics’ manufacturing services and progress on ZYNYZ, which matter for service revenue and possible milestones—not the royalties MacroGenics has sold.
Watch for Incyte’s disclosed need for manufacturing services and for development or commercial progress on ZYNYZ. Continued production needs support MacroGenics’ service revenue and help cover facility costs; reaching a contractual ZYNYZ milestone could bring a separate payment. Weaker demand or stalled progress would limit those respective opportunities. MacroGenics has sold its ZYNYZ royalty rights.
AstraZeneca PLC earningsAZN
AstraZeneca’s report and clinical disclosures can show whether antibody treatments competing with MacroGenics’ cancer programs are advancing, adding to or easing competitive pressure.
Watch AstraZeneca’s disclosed clinical progress in PD-1 or PD-L1 plus CTLA-4 bispecific antibodies, and in antibody-drug conjugates (ADCs), which carry a drug payload on an antibody. Progress could intensify competition for doctors, patients, and clinical resources faced by MacroGenics’ programs; setbacks could ease that pressure, but would not prove MacroGenics’ candidates are more effective or safer.
Sanofi earningsSNY
Sanofi’s report and disclosures can show how TZIELD sales are progressing; only reaching the specified sales threshold could trigger MacroGenics’ retained $50 million payment.
Watch Sanofi’s disclosed TZIELD sales and whether they approach the agreed threshold. Stronger sales that reach the threshold could trigger MacroGenics’ retained $50 million payment; sales that do not meet the condition would not. Sanofi’s overall revenue alone cannot establish that the threshold was reached.
MacroGenics, Inc. earningsThis company
MacroGenics’ report will show whether contract manufacturing revenue covers the cost of providing those services and eases reliance on variable collaboration income.
Compare contract manufacturing revenue with the related cost of manufacturing services, then check how much collaboration revenue comes from milestone payments. If service revenue exceeds its costs and collaboration income is not mainly milestone-driven, outside work is doing more to support research and development. If costs exceed service revenue and collaboration income relies on milestones, the business has less dependable income to offset its cash use.
